CapsoVision, Inc
CapsoVision is a medical technology company that develops diagnostic and screening products to identify abnormalities of the gastrointestinal tract. Headquartered in Saratoga, California, it sells a capsule endoscopy solution consisting of the single-use CapsoCam capsule and associated CapsoCloud and CapsoView software. CapsoCam Plus, its cleared small-bowel capsule, is used to visualize the small-bowel lining in adults and children aged 2 years and above. The capsule captures panoramic video and stores it in onboard memory; healthcare providers can stream video through CapsoCloud or download and review it using CapsoView. CapsoVision sells CapsoCam Plus in the U.S. primarily to gastroenterologists in clinics and hospitals through its in-house sales team. Outside the U.S., it sells through its in-house team and qualified distributors. The company is developing CapsoCam Colon, a capsule for colon visualization and polyp detection and measurement, as well as a capsule delivery device and a patency capsule.
No enriched coverage for $CV in the last 7 days.
No SEC Form 4 filings for $CV in the last 30 days.
See all $CV insider activity →CapsoVision completed a pivotal study for its colon capsule and plans FDA submission in Q4. The company cited a $17.8B colon screening market, with the capsule priced at $600 vs. $3,500-$5,000 for conventional colonoscopies. CapsoVision reported $13.6M revenue in 2025, up 15% YoY, with a 53% gross margin. The company is also pursuing pancreatic and esophageal applications.
Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.
CapsoVision (CV) received FDA clearance for its AI Highlights tool, designed to assist physicians in reviewing small bowel capsule endoscopy studies. The tool reduces review time by marking suspected abnormal lesions. AI Highlights integrates with CapsoView and CapsoCloud platforms. CV's stock is currently trading at $6.63, down 0.38%.
Recent CV coverage spans regulation, technology and insider activity.
Positive product development and funding news may lift CV as FDA submission approaches.
Clearance may improve product adoption, modestly supportive for the stock.
Positive regulatory approval expands product offering and may boost sales.
The clearance is expected to boost investor sentiment and support the stock price.
Large insider buy may signal confidence, potential upside.
AlphAI scores every news story that mentions CV with an AI model for sentiment and relevance, and aggregates insider trades from CapsoVision, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
CapsoVision completed a pivotal study for its colon capsule and plans FDA submission in Q4. The company cited a $17.8B colon screening market, with the capsule priced at $600 vs. $3,500-$5,000 for conventional colonoscopies. CapsoVision reported $13.6M revenue in 2025, up 15% YoY, with a 53% gross margin. The company is also pursuing pancreatic and esophageal applications.
Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.
CapsoVision (CV) received FDA clearance for its AI Highlights tool, designed to assist physicians in reviewing small bowel capsule endoscopy studies. The tool reduces review time by marking suspected abnormal lesions. AI Highlights integrates with CapsoView and CapsoCloud platforms. CV's stock is currently trading at $6.63, down 0.38%.
CapsoVision, Inc (CV) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus® AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system SARATOGA, Calif., September
CapsoVision (CV) director bought $9.9M shares at $5.69 each. Corebridge (CRBG) 10% owner Nippon Life bought $7.47M shares at $35.08. Inhibrx (INBX) director bought $500K shares at $100. Diamondback (FANG) director sold $15.32M shares at $204.31. Arista (ANET) CTO sold $8.82M shares near 52-week high. Duolingo (DUOL) CEO sold $6.17M shares at $150-$152. Asana (ASAN) CEO sold $4.2M shares. Robinhood (HOOD) CEO sold $32.55M shares.
HARARI ELIYAHOU ET AL purchased 1,757,469 indirectly-held shares of CapsoVision, Inc (CV) at $5.69 ($10.00M total) across 2 trades on 2026-09-18.
Shen Ching Hang purchased 878,734 indirectly-held shares of CapsoVision, Inc (CV) at $5.69 ($5.00M total) on 2026-09-15.
CapsoVision, Inc (CV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 17, 2026, CapsoVision, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), which provides for the issuance and sale, in a regist
CapsoVision, Inc (CV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CapsoVision Reports Second Quarter 2026 Financial Results SARATOGA, Calif., August 13, 2026 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financia
CapsoVision (NASDAQ: CV) said it launched its AI Highlights feature for the CapsoCam Plus capsule endoscopy system in international markets, including the EU. The AI flags suspected clinically relevant frames during standard processing and integrates with CapsoView and CapsoCloud workflows. The update is offered where authorized; it is not cleared by the FDA for US sale.
